According to our (Global Info Research) latest study, the global Long-acting ESAs market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Long-acting erythropoiesis-stimulating agents (ESAs) are medications designed to stimulate red blood cell production over an extended period, reducing the frequency of administration compared to traditional ESAs. These drugs, such as darbepoetin alfa and methoxy polyethylene glycol-epoetin beta, are modified to have a prolonged half-life, allowing for less frequent dosing—typically once every two to four weeks—while maintaining their effectiveness in treating anemia. Long-acting ESAs are commonly used to treat anemia related to chronic kidney disease (CKD) and chemotherapy-induced anemia.
This report is a detailed and comprehensive analysis for global Long-acting ESAs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Long-acting ESAs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Long-acting ESAs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Long-acting ESAs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Long-acting ESAs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting ESAs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting ESAs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Kyowa Kirin, Amgen, Dr. Reddy's Laboratories, Roche, Hansoh Pharma, Cipla, Sanwa Kagaku Kenkyusho, Kissei Pharmaceutical, Kyowa Hakko Kirin, Torrent Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Long-acting ESAs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Darbepoetin Alfa
Methoxy Polyethylene Glycol-Epoetin Beta
Pegmolesatide
Market segment by Application
Renal Anemia
Cancer
Other
Major players covered
Kyowa Kirin
Amgen
Dr. Reddy's Laboratories
Roche
Hansoh Pharma
Cipla
Sanwa Kagaku Kenkyusho
Kissei Pharmaceutical
Kyowa Hakko Kirin
Torrent Pharmaceuticals
CKD Pharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-acting ESAs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting ESAs, with price, sales quantity, revenue, and global market share of Long-acting ESAs from 2021 to 2026.
Chapter 3, the Long-acting ESAs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting ESAs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Long-acting ESAs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting ESAs.
Chapter 14 and 15, to describe Long-acting ESAs sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Long-acting ESAs. Industry analysis & Market Report on Long-acting ESAs is a syndicated market report, published as Global Long-acting ESAs Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Long-acting ESAs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.